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Natural killer (NK) cells are innate lymphoid cells involved in the defense against virus-
infected cells and tumor cells. NK cell phenotype and function is affected with age and 
cytomegalovirus (CMV) latent infection. Aging affects the frequency and phenotype of 
NK cells, and CMV infection also contributes to these alterations. Thus, a reduction 
of CD56bright NK cell subpopulation associated with age and an expansion of memory-
like NK cells CD56dimCD57+NKG2C+ probably related to CMV seropositivity have 
been described. NK cells express T-bet and Eomes transcription factors that are 
necessary for the development of NK cells. Here, we analyze the effect of age and 
CMV seropositivity on the expression of CD300a and CD161 inhibitory receptors, and 
T-bet and Eomes transcription factors in NK cell subsets defined by the expression 
of CD56 and CD57. CD300a is expressed by the majority of NK cells. CD56bright 
NK cells express higher levels of CD300a than CD56dim NK cells. An increase in the 
expression of CD300a was associated with age, whereas a decreased expression of 
CD161 in CD56dim NK cells was associated with CMV seropositivity. In CD56dim NK 
cells, an increased percentage of CD57+CD300a+ and a reduction in the percentage 
of CD161+CD300a+ cells were found to be associated with CMV seropositivity. 
Regarding T-bet and Eomes transcription factors, CMV seropositivity was associated 
with a decrease of T-bethi in CD56dimCD57+ NK cells from young individuals, whereas 
Eomes expression was increased with CMV seropositivity in both CD56bright and 
CD56dimCD57+/− (from middle age and young individuals, respectively) and was 
decreased with aging in all NK subsets from the three group of age. In conclusion, 
CMV infection and age induce significant changes in the expression of CD300a and 
CD161 in NK cell subsets defined by the expression of CD56 and CD57. T-bet and 
Eomes are differentially expressed on NK cell subsets, and their expression is affected 
by CMV latent infection and aging.
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inTrODUcTiOn
Natural killer (NK) cells are lymphocytes of innate immune 
response responsible for killing virus-infected cells and tumor 
cells. Frequency, phenotype, and function of NK cell subsets 
change in aging, and these changes are considered part of a 
general process of age-associated immune dysfunctions defined 
as immunosenescence (1–4). Immunosenescence affects adap-
tive and innate immunity, and it is associated with increased 
incidence and severity of infections and decreased response to 
vaccination (5–11).
It has been shown that percentage of CD56dim NK cell subset 
(the main subset of NK cells and most cytotoxic) is increased (12, 
13) or maintained (14) by age, whereas percentage of immature 
CD56bright NK cells is decreased (12–15). On the other hand, the 
expression of different receptors on NK cells is also altered in 
aging (16–18). It has been found a decrease in the expression of 
natural cytotoxicity receptors (such as NKp30 and NKp46) and 
activating receptor DNAM-1 on CD56dim NK subset (3, 19–21) 
an increased expression of CD57 (18, 20, 22), as well as reciprocal 
changes in NKG2A and killer immunoglobulin-like (KIR) inhibi-
tory receptors, associated with age (18, 20, 22).
Human cytomegalovirus (CMV) chronic infection is related 
to a deterioration of the immune system that affect adaptive and 
innate immunity, and it has been postulated that CMV infection 
is a major driving force contributing to immunosenescence (10, 
23, 24). CMV is a human herpesvirus type 5 (HHV5), which 
replicate in different cell types. Although CMV seropositivity is 
influenced by geographic, ethnic, and socio-economical factors, 
it has been shown that it increases with age in all populations 
studied (25). CMV prevalence is very high in Spain and more 
than 80% of individuals over the age of 40  years are CMV-
seropositive (26).
Cytomegalovirus seropositivity can reshape the repertoire 
of NK cells (2, 27), particularly with an expansion of NKG2C+ 
NK cells, which also coexpress CD57 marker (14, 28, 29). 
Recent studies stratifying donors according to CMV serology 
have shown that increase of CD57 expression on CD56dim NK 
cells is related to CMV seropositivity rather than aging (14) 
as well as the decreased expression of other surface receptors 
of NK cells, such as NKp30 (30) or CD161 (31). Thus, aging 
is associated with a loss of CD56bright NK cell subpopulation 
(probably due to a decrease in the production of new NK cells 
in the bone marrow) and an expansion of memory-like NK 
cells CD56dimCD57+NKG2C+ that is mainly related to CMV 
seropositivity [reviewed in Ref. (2)].
Although it is well established that aging and CMV infection 
are associated with changes in NK cells, including alterations in 
the expression of activating (e.g., NCRs, NKG2C, and DNAM-1) 
and inhibitory receptors (e.g., KIR and NKG2A), little is known 
on the effect of aging and CMV on the expression of other inhibi-
tory receptors such as CD300a and CD161 in NK cell subpopula-
tions. CD300a is an inhibitory receptor expressed by NK cells 
that belongs to the CD300 family of molecules. These receptors 
are broadly expressed on immune cells and modulate their func-
tion via paired activating and inhibitory receptors that recognize 
lipids exposed on the plasma membrane of dead and activated 
cells including aminophospholipids such as phosphatidylserine 
(PS) and phosphatidylethanolamine (PE) (32). The analysis of 
its expression can be used in diagnosis and therapy in several 
pathological situations including infectious diseases, allergy, or 
cancer [for review, see Ref. (33)]. The human CD161 inhibitory 
receptor (also termed NKR-P1A, KLRB1, and CLEC5B) was 
originally described as a disulfide-linked homodimer of the 
C-type lectin superfamily expressed on subsets of NK cells and 
T lymphocytes (34) that binds the lectin-like transcript 1 (LLT1, 
also named CLEC2D, OCIL, and CLAX) (35, 36). The binding 
of CD161 on NK cells with its ligand on target cells results in 
inhibition of NK cell cytotoxicity by a mechanism involving 
the activation of acid sphingomyelinase (37). CD161 can also 
be expressed on subsets of other cells of the immune system, 
and different functional capacities have been shown after the 
interaction with its ligand, which can be upregulated during 
the  immune response and during pathological circumstances. 
The current knowledge of NKRP1 receptors and their geneti-
cally linked CLEC2 ligand in human and other species has been 
recently reviewed (38, 39).
Natural killer cells are included in group 1 of the innate 
lymphoid cell (ILC), characterized by the release of interferon-
gamma (IFN-γ) upon stimulation, and by the expression of 
T-bet and eomesodermin (Eomes) transcription factors 
(40–42). Both T-bet and Eomes are constitutively expressed by 
murine (43) and human (44, 45) NK cells and are necessary 
for the proper development of NK cells (46), sharing several 
functions. It has been observed that the frequency of T-bet+ 
cells and the level of T-bet expression per cell is significantly 
greater in the CD56dim population compared to the CD56bright 
population from peripheral human immune cells, contrary to 
Eomes expression pattern, suggesting the existence of a relation-
ship among the expression levels of both transcription factors 
and the functionality of these cells (45). Thus, T-bet is related 
to terminal stages of maturation, while Eomes is downregulated 
during peripheral maturation (47).
Considering that aging affects the frequency and phenotype 
of NK cells and that CMV infection contributes to age-associated 
changes in NK cells; in this work, we have analyzed the effect 
of age and CMV seropositivity on inhibitory receptors CD300a 
and CD161 in NK cell subpopulations. Additionally, we have 
investigated the effect of age and CMV infection on T-bet and 
Eomes transcription factors expression in the CD56brightCD57−, 
CD56dimCD57−, and CD56dimCD57+ NK cell subsets.
MaTerials anD MeThODs
study subjects
A total of 72 healthy adults voluntarily participated in the study, 
stratified according to age: 18–35  years (young), 40–65  years 
(middle age), and >70  years (old). Young and middle age 
donors were further divided according to CMV serology 
(CMV-seropositive and CMV-seronegative). However, all elderly 
donors included in the study were CMV-seropositive, given that 
the prevalence of CMV seropositivity in Spain in individuals 
over the age of 40 years is 80% (26) and, in our geographic area 
(Andalusia, Southern Spain), about 99% of individuals over 
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65  years are CMV-seropositive. Thus, the absence of a group 
of CMV-seronegative old donors represents a limitation of the 
study, making difficult to isolate age-related effect from the effect 
of chronic CMV infection in elderly individuals.
All donors were informed and signed informed consent to 
participate in the study and were included according to follow-
ing inclusion criteria: no infection at the time of extraction, not 
suffer or have suffered cancer or autoimmune diseases, and not 
be under immunosuppressive drugs or calcium channel block-
ers. The study was approved by the Ethics Committee of Hospital 
Universitario Reina Sofia of Córdoba (Spain).
sample collection and Processing
Peripheral blood mononuclear cells (PBMCs) were obtained from 
blood samples (collected in lithium heparin tubes) and isolated 
by density gradient centrifugation using Ficoll Histopage-1077 
(Sigma-Aldrich, St. Louis, MO, USA). Aliquots of cells were cryo-
preserved in FBS (Sigma-Aldrich, St Louis, MO, USA) with 10% 
DMSO (Panreac Chemistry SAU, Barcelona, Spain) in cryotubes 
at concentrations 5–6 × 106 cells/mL until further use.
A sample of plasma or serum was retrieved from all donors 
to analyze CMV-specific IgG and IgM. CMV serology was deter-
mined by using automated enzyme-linked immunosorbent assay 
(ELISA) (DRG International, Mountainside, NY, USA).
analysis of nK cell receptors by 
Flow cytometry
For surface marker analysis and computation of frequency of cells 
expressing CD57, CD161, or CD300a, cryopreserved PBMCs 
were used. Cell thawing was carried out in RPMI 1640 (Sigma-
Aldrich) with 20% FBS (Gibco, Life Technologies California, 
USA). For flow cytometry staining, the following antibodies 
(mAbs) were used: anti-CD3 PerCP (clone: BW 264/56, Miltenyi 
Biotec), anti-CD56 PE-Cy7 (clone: B159, BD Pharmingen), anti-
CD57 VioBlue (clone: TB03, Miltenyi Biotec), anti-CD300a PE 
(clone: E59.126, Beckman Coulter), and anti-CD161 APC (clone: 
DX12, BD Pharmingen). Cells were acquired on a MACSQuant 
cytometer (Miltenyi Biotec, Bergisch Gladbach, Germany). 
Compensation for flow cytometry was performed using single 
cell staining.
Data were analyzed using FlowJo v10 (Tree Star, Inc.). 
CD3−CD56+ NK cells were gated from total peripheral blood lym-
phocytes (PBLs), after singlets gating (Figure S1 in Supplementary 
Material). Two NK cell subsets were defined (CD56bright and 
CD56dim) according to the level of CD56 marker expression. 
Subsequently, cells were gated according to the coexpression of 
CD57, CD161, and CD300a markers. Fluorescence minus one 
controls (FMO control) were used to identify and gate cells. FMO 
controls contain all the fluorochromes of the panel, except the one 
that was being measured. Analysis of coexpression of the three 
receptors was performed using FlowJo’s Boolean gating options.
Transcription Factors expression analysis
The expression of T-bet and Eomes transcription factors was 
analyzed using cryopreserved PBMCs, thawed as indicated 
above. Surface staining was performed using anti-CD7 APC 
(clone: M-T701, BD Pharmingen), anti-CD56 BV421 (clone: 
NCAM16.2, BD Horizon), anti-CD16 PE- Vio770 (clone: VEP13, 
Miltenyi Biotec), anti-CD57 Biotin-Anti-Biotin-Viogreen 
(Miltenyi Biotec), and anti-CD3/anti-CD14/anti-CD19 con-
jugated with APC-Vio770 (clones: BW264/56, TÜK4, LT19 
Miltenyi Biotec). After cell fixation and permeabilization using 
the Kit FoxP3 Staining Buffer Set (Miltenyi Biotec), following the 
manufacturer’s instructions, intracellular staining was realized 
with anti-T-bet PerCP Cy5.5 (clone: 04-46, BD Pharmingen) and 
anti-Eomes FITC (clone: WD1928, eBioscience) antibodies. Cells 
were then acquired on a 10 parameter MACSQuant cytometer 
(Miltenyi Biotec, Bergisch Gladbach, Germany).
Data were analyzed using FlowJo v10 (Tree Star, Inc.). Once 
selected the CD7+CD3−CD19−CD14− cells from PBLs singlets, 
three populations of NK cells were described: CD56brightCD57−, 
CD56dimCD57−, and CD56dimCD57+. Then, the intracellular 
expression of T-bet and Eomes was measured in each of these 
three subpopulations (Figure S2 in Supplementary Material). 
FMO controls and flow cytometry compensation were performed 
as indicated above.
Processing of Data and statistical 
analysis
For statistical analysis, Shapiro–Wilk normality test was 
performed for different groups. Since the distribution of meas-
ured values was not normal, the groups were evaluated by the 
non-parametric Kruskal–Wallis test (for comparison multiple) 
and Mann–Whitney test (for comparison sample pairs). 
Non-parametric Friedman test (for comparison multiple) and 
Wilcoxon test were used to test for differences between groups 
when the samples are related. The results are shown in graphs 
with interquartile medium range using GraphPad Prism (version 
5.0), and analysis of Boolean gating data was performed by SPICE 
5.35 software (Mario Roederer, ImmunoTechnology Section, 
Vaccine Research Centre, NIH, Bethesda, MD, USA; http://www.
niaid.nih.gov) (48). To compare the pie charts, we used SPICE’s 
permutation analysis, which asks how often the samples that 
comprise two different pies charts, would be different simply by 
chance (10,000 permutations). All statistical analysis was per-
formed with SPSS 18.0 (SPSS Inc., Chicago, IL, USA). p-Values 
<0.05 were considered significant.
resUlTs
increase of cD300a and Decrease of 
cD161 expression from cMV-seropositive 
Old individuals
We analyzed by flow cytometry the expression of CD300a and 
CD161 inhibitory receptors on NK cells (CD56bright and CD56dim) 
from healthy individuals stratified by age and CMV latent infec-
tion. Our data showed that both receptors exhibit a differential 
expression pattern. Particularly, the majority of CD56dim and 
CD56bright NK cells expressed CD300a, whereas CD161 was 
expressed on a subpopulation of NK cells regardless of the 
NK cell subset analyzed (Figure S1 in Supplementary Material). 
Moreover, when we gated the NK cell subsets according to CD56 
FigUre 1 | cD300a and cD161 expression on cD56dim and cD56bright nK cells from young, middle age, and old individuals, according to cMV 
seropositivity.
(Continued)
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and CD300a (referred to CD3− cells), we observed that the major-
ity of CD56bright NK cells were CD300ahi, whereas a high percent-
age of CD56dim NK cells were CD300alo (Figure  1A). Analysis 
of the effect of age and CMV seropositivity on the expression 
of these receptors by NK cell subsets (gating strategy in Figure 
S1 in Supplementary Material) showed an increase of CD300a 
on CD56bright and CD56dim subsets from CMV-seropositive old 
individuals compared with middle-aged and young donors 
(independently of CMV seropositivity) (Figure 1B).
The analysis of CD161 expression on CD56dim NK cells 
showed that young CMV-seronegative donors expressed higher 
levels of CD161 than young CMV-seropositive or middle age 
CMV-seronegative individuals, supporting that CMV and age 
independently associated with decreased expression of CD161 in 
FigUre 1 | continued  
(a) Differential expression of CD300a on NK cell subsets. NK cells were defined as CD3−CD56+ and characterized by CD300a expression as CD56brightCD300ahi and 
CD56dimCD300alo. (B) Effect of age and CMV seropositivity on the expression of CD300a and CD161. Expression (percentage) of CD300a and CD161 markers was 
determined on NK cell subsets from young CMV-seronegative (n = 22), young CMV-seropositive (n = 15), middle age CMV-seronegative (n = 8), middle age 
CMV-seropositive (n = 13), and old CMV-seropositive donors (n = 14). CD56+CD3− NK cells were gated from singlets peripheral blood lymphocytes (PBLs). Then, 
two NK cell subsets were defined (CD56bright and CD56dim) according to the level of CD56 marker expression, and cells were gated according to the expression of 
CD57, CD161, and CD300a markers. Non-parametric Kruskal–Wallis test (for multiple comparisons) and Mann–Whitney test (for paired comparisons) was used. 
Graphs showed the median with interquartile range, and results were considered significant at *p < 0.05, **p < 0.01, and ***p < 0.001.
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this NK cell subset. On the contrary, the expression of CD161 
on CD56bright NK cells was not affected by CMV seropositivity 
in young donors, whereas it was decreased in middle age CMV-
seronegative individuals. The expression of CD161 was lower on 
both NK cell subsets in middle age and old CMV-seropositive 
donors compared with young CMV-seronegative individuals 
(Figure 1B).
These results indicate an expansion of CD300a+ on NK cell 
subsets (CD56bright and CD56dim) from healthy old individuals 
(all CMV-seropositive), likely associated with the combined 
effect of CMV infection and age, and a decrease of CD161+ NK 
cells related to CMV seropositivity (CD56dim NK cells) and age 
(CD56bright and CD56dim NK cells).
In this analysis, we have also observed an increased percentage 
of CD56dimCD57+ NK cells associated with CMV seropositivity. 
Also, CD56bright NK cells do not express or express very low levels 
of CD57 on their surface (data not shown).
coexpression of cD300a, cD161, 
and cD57 on nK cell subsets
The coexpression of CD300a, CD161, and CD57 was measured 
on CD56dim and CD56bright NK cells using FlowJo’s Boolean 
gating options. The majority of CD56bright and CD56dim NK cells 
expressed CD300a on their surface, either alone or in combina-
tion with CD161 or CD57. A minor subset of CD300a+ NK cells 
coexpressed CD161 and CD57 (Figure 2A).
The results on the effect of age and CMV seropositivity on 
the coexpression of CD300a, CD161, and CD57, revealed that 
CMV seropositivity, but not age, was associated with an increase 
of CD56dim NK cells coexpressing CD300a and CD57. We also 
observed a decrease of CD56dimCD300a+CD161+ NK cells related 
to both CMV seropositivity and age. No significant differences 
were found in the percentage of CD56dimCD300a+CD57− 
CD161− NK cells among the different groups studied (data not 
shown). On the other hand, we have also observed an increase 
of CD56brightCD300a+CD57−CD161− NK cells and a decrease of 
CD56bright coexpressing CD300a and CD161 in old individuals 
(Figures 2A,B).
Different expression Patterns of T-bet 
and eomes Transcription Factors in 
nK cell subsets
We analyzed the expression of T-bet and Eomes transcription 
factors in three subpopulations of NK cells, according to the 
FigUre 2 | coexpression of cD57, cD161, and cD300a in nK cell subsets. 
(Continued)
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expression of CD56, CD16, and CD57 markers: CD56brightCD16+/− 
CD57−, CD56dimCD16+CD57−, and CD56dimCD16+CD57+ NK 
cells (Figure S2 in Supplementary Material). Although Eomes was 
expressed in most NK cells in all groups studied, the analysis of 
its expression pattern showed higher levels in the most immature 
NK cells (CD56brightCD16+/−CD57−) with a decline in its expres-
sion in the CD56dimCD16+CD57− and in the most differentiated 
NK cells (CD56dimCD16+CD57+) (Table 1).
The expression of T-bet in NK cell subsets showed a gradient 
of expression and two subsets can be distinguished: T-bethi and 
FigUre 2 | continued  
(a) CD57, CD161, and CD300a expression profile (pie charts) in CD56dim and CD56bright NK cells from 72 healthy individuals stratified by age and CMV serostatus. 
Analysis of coexpression of three receptors was performed using FlowJo’s Boolean gating options. For analysis of complex multivariate datasets after of flow 
cytometry, we used the application simplified presentation of incredibly complex evaluations (SPICE). (B) Graphs show the coexpression of CD57/CD161/CD300a 
NK subsets in which we found statistical differences among the four groups studied. Non-parametric Kruskal–Wallis test (for multiple comparisons) and Mann–
Whitney test (for paired comparisons) were used. Graphs showed the median with interquartile range. Results were considered significant at *p < 0.05, **p < 0.01, 
and ***p < 0.001.
TaBle 1 | eomes expression (MFi) in nK subsets from donors stratified according to age and cMV seropositivity.
cD56brightcD16−cD57− (1) cD56dimcD16+cD57− (2) cD56dimcD16+cD57+ (3) ρ ρ (1–2) ρ (2–3) ρ (1–3)
Young CMV− 3.47 (4.46–2.58)a 2.12 (2.23–1.35) 1.59 (1.78–0.84) 0.000 0.005 0.005 0.005
Young CMV+ 3.75 (4.91–2.35) 2.28 (2.67–1.9) 2.18 (2.34–1.58) 0.007 0.007 0.169 0.007
Middle age CMV− 3.48 (4.74–2.33) 1.87 (2.41–1.65) 1.45 (2.4–1.28) 0.001 0.018 0.018 0.018
Middle age CMV+ 3.32 (4.54–2.96) 2.15 (2.52–1.67) 1.6 (2.1–1.41) 0.000 0.008 0.008 0.008
Old CMV+ 3.02 (3.79–2.46) 2.01 (2.71–1.59) 1.8 (2.05–1.2) 0.000 0.005 0.005 0.005
aValues expressed as median (interquartile range, 75–25).
ρ value obtained by the Friedman rank sum test.
ρ values comparing (1–2), (2–3), and (1–3) groups obtained by the Wilcoxon test.
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T-betint NK cells. The percentage of NK cells expressing T-bethi 
was higher than the percentage of NK cells expressing T-betint 
in the three subsets studied (Figure S2 in Supplementary 
Material). The analysis of T-bet MFI in the different NK cell 
subsets showed that T-bet expression was lower in CD56bright 
CD16+/−CD57− NK cells from each group studied than in 
CD56dimCD16+CD57− and CD56dimCD16+ CD57+ NK cells into 
the same group (Table 2).
The analysis of Eomes expression in NK cell subsets 
from CMV-seronegative and CMV-seropositive individuals 
showed that the percentage of positive cells was significantly 
increased in CD56brightCD16+/−CD57− NK cells from CMV-
seropositive middle age donors and in CD56dimCD16+CD57+ 
and CD56dimCD16+CD57− from CMV-seropositive young 
donors compared with the CMV-seronegative counterparts 
(Figures  3A,B). The analysis of the effect of age on Eomes 
expression showed a decreased expression in CD56brightCD
16+/−CD57− NK cells from CMV-seronegative middle age 
donors compared with CMV-seronegative young individuals 
(Figure  3A). Eomes expression in CMV-seropositive donors 
was significantly higher in the young compared with the middle 
age and old groups in the three NK cell subsets considered 
(Figures 3A,B).
The effect of age and CMV seropositivity on T-bet expression 
was also analyzed. The results only showed a significant decrease 
in the percentage of T-bethi within the CD56dimCD16+CD57+ 
NK cell subset from CMV-seropositive compared with CMV-
seronegative young donors (Figures 3C,D).
DiscUssiOn
Cumulative evidences in the last decade support that aging 
and CMV latent infection combine to influence the immune 
phenotype and function of immune cells, including NK cells, in 
different ways that have been often overlooked in studies aiming 
to analyze the effect of aging on NK cells without considering the 
CMV serostatus of the individuals studied.
In this work, we have analyzed the effect of CMV sero-
positivity and aging on the expression of CD300a and 
CD161 receptors and transcription factors T-bet and Eomes 
on peripheral blood NK cell subsets with different levels of 
maturation.
TaBle 2 | T-bet expression (MFi) in nK subsets from donors stratified according to age and cMV seropositivity.
cD56brightcD16−cD57− (1) cD56dimcD16+cD57− (2) cD56dimcD16+cD57+ (3) ρ ρ (1–2) ρ (2–3) ρ (1–3)
Young CMV− 6.31 (10.2–2.91)a 8.84 (12.6–5.89) 9.31 (12.5–6.24) 0.000 0.008 0.022 0.005
Young CMV+ 7.17 (10.3–3.47) 10.84 (12.2–7.26) 9.64 (11.4–7.49) 0.000 0.005 0.011 0.008
Middle age CMV− 10.10 (13–1.89) 12.8 (13.8–5.77) 13.2 (13.8–5.84) 0.004 0.043 0.042 0.018
Middle age CMV+ 7.09 (10.8–3.85) 10.3 (13.5–6.97) 10.7 (13.9–6.79) 0.003 0.008 0.285 0.011
Old CMV+ 4.85 (11.3–2.79) 7.57 (11.6–6.42) 7.22 (10.6–5.95) 0.007 0.017 0.013 0.114
aValues expressed as median (interquartile range, 75–25).
ρ value obtained by the Friedman rank sum test.
ρ values comparing (1–2), (2–3), and (1–3) groups obtained by the Wilcoxon test.
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Our results show that CD57+CD56dim NK cells are expanded 
in CMV-seropositive individuals and that these cells are not 
further expanded by aging. In addition, the majority of these 
cells also coexpress CD300a, but not CD161. The expansion 
of CD57+CD56dim NK cells support previous data showing 
that acute and latent CMV infection leads to the expansion of 
CD57+CD56dim NK cells that also express NKG2C+ (28, 49–54). 
CMV seropositivity is also associated with a decreased expression 
of other NK receptors, in some cases, as a consequence of the shift 
of NK cells to the more differentiated NKG2C+CD57+ phenotype 
(14, 27, 30, 54). These cells have some characteristics of adaptive 
immunity and are considered “memory” or “adaptive” NK cells 
(55–58). The magnitude of the expansion of NKG2Chigh NK cells 
is determined by the magnitude of the proinflammatory cytokine 
secretion upon NK cell activation (59), and it has been proposed 
that these cells contribute to the proinflammatory environment 
based on the relation between the percentage of NKG2C+ cells, 
elevated levels of PCR, and cardiovascular risk determinants of 
CMV-seropositive individuals (60, 61).
Whereas it has been show that both aging and CMV infection 
are associated with a decreased expression of several NK activat-
ing receptors (with the exception of NKG2C that is increased in 
CMV-seropositive individuals), their effect on the expression of 
inhibitory receptors is still controversial. Thus, whereas different 
studies have shown an age-associated increased expression of 
KIR (20, 62) and a decreased expression of NKG2A (20), others 
have not found significant differences in the expression of KIR or 
NKG2A in the elderly (14, 17, 18, 30) or even a decreased expres-
sion of KIR (CD158a) in middle age donors if they are CMV-
seropositive (63). The expression of another inhibitory receptor 
KLRG-1 is significantly reduced with aging (21) and with CMV 
seropositivity in the young individuals (63).
The inhibitory receptor CD300a is expressed on the majority 
of NK cells, and its expression increases with aging in CMV-
seropositive individuals both in CD56bright and CD56dim NK cell 
subsets. As stated in Section “Materials and Methods,” in our 
geographic area (Andalusia, Southern Spain), about 99% of 
individuals over 65 years are CMV-seropositive. Thus, the high 
prevalence of CMV in our geographic area supposes a limitation 
of the study as we lack of a group of CMV-seronegative elderly 
donors. This limitation makes difficult to assess the differential 
effect of CMV and aging when we observe changes only in the 
group of old CMV-seropositive individuals compared with the 
other groups. This is the case of the higher expression of CD300a 
found in old CMV-seropositive individuals compared with the 
other groups studied. Since we do not observe an effect of CMV 
seropositivity between in the young and middle age groups, it 
could be thought that the higher expression of CD300a found in 
old CMV-seropositive individuals is likely due to aging. However, 
due to this limitation, we can only conclude that aging has an effect 
on CD300a expression on CMV-seropositive donors. CD300a is 
an inhibitory receptor that can be expressed by NK cells and that 
deliver inhibitory signals upon binding to PS expressed by tumor 
cells (64). The binding of CD300a on human or porcine NK cells 
to the surface of the pseudorabies virus porcine infected cell is 
increased by the US3 protein kinase of this alpha-herpesvirus in 
an aminophospholipids and p21-activated kinases dependent way, 
providing protection of infected cells against NK cell cytotoxicity 
(65). These results support the possible relevance of CD300a as a 
possible NK cell evasion strategy by CD300a-modulating viruses 
and cancer cells.
Although CD300a is highly homologous to CD300c and 
both receptors are considered as paired receptors with inhibi-
tory and activating roles, respectively, very little is known on 
the expression and function of CD300c on NK cells. It has been 
recently shown that NK cells do not express (or express very low 
levels of) CD300c and that its expression is induced uniquely 
on CD56bright NK cells after their treatment with IL-2 or IL-15 
(66). The analysis of the interaction of CD300a and CD300c 
with their ligands shows differences on their binding affinity 
to the lipid ligands. Whereas both CD300a and CD300c show 
similar binding to PS, it has been shown that CD300a exhibits 
a stronger binding to dead cells and to PE than CD300c and PE 
induces a negative response of IL-2 preactivated CD56bright NK 
cells, supporting that the inhibitory signals triggered by CD300a 
after binding to its lipid ligands overrides the signals triggered 
by its activating counterpart CD300c (66). These findings are 
consistent with these shown for other paired receptors such as 
KIR2DL1 and CD94/NKG2A that have higher binding affinity 
to HLA-CLys80 and HLA-E, respectively, than their activating 
counter parts KIR2DS1 and CD94/NKG2C. The increased 
expression of CD300a with aging both in CD56bright and CD56dim 
subsets can contribute together with other age-associated altera-
tions of NK cells to the decreased functional capacity of these 
cells in the elderly.
The human CD161 receptor, expressed in a subset of NK cells, 
is an inhibitory receptor that, after interacting with its ligand 
LLT1, inhibits NK cell cytotoxicity by a mechanism involving 
the activation of acid sphingomyelinase (37). Our results show 
that the expression of CD161 on CD56dim NK cells is decreased 
FigUre 3 | effect of age and cMV seropositivity on eomes and T-bet expression. The expression of T-bet and Eomes was measured in 
CD56brightCD16+/−CD57−, CD56dimCD16+CD57−, and CD56dimCD16+CD57+ NK cells from 46 healthy individuals (10 young CMV-seronegative, 10 young CMV-
seropositive, 7 middle age CMV-seronegative, 9 middle age CMV-seropositive, and 10 old CMV-seropositive donors). (a) Analysis of Eomes expression in 
CD56brightCD16+/−CD57− NK cells. (B) Analysis of Eomes expression in CD56dimCD16+CD57− and CD56dimCD16+CD57+ NK cells (c) Analysis of T-bet expression in 
CD56brightCD16+/−CD57− NK cells. (D) Analysis of T-bet expression in CD56dimCD16+CD57− and CD56dimCD16+CD57+ NK cells. Non-parametric Kruskal–Wallis test 
(for multiple comparisons) and Mann–Whitney test (for paired comparisons) were used. Graphs showed the median with interquartile range. Results were considered 
significant at *p < 0.05, **p < 0.01, and ***p < 0.001.
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in CMV-seropositive donors compared with young CMV-
seronegative donors. Little is known regarding the effect of CMV 
and aging on the expression of CD161 on NK cell subsets. The 
analysis of telomere length in NK cells has shown that the average 
telomere length in human NK cells decrease with age. In addition, 
the telomere length was significantly shorter in CD56dimCD16+ 
NK cells compared to CD56brightCD16− NK cells from the same 
donor indicating that this subset represents more immature NK 
cells (67). In this study, it was shown that although CD161 can 
be expressed on CD56bright and CD56dim subsets, its expression 
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is independent of the level of differentiation estimated by the 
telomere length (67).
The expression of CD161 in T lymphocytes and NK cells in 
PBLs from healthy children appears unrelated to CMV serostatus 
(68). On the contrary, it has been reported that NKG2C+CD56dim 
NK  cells, expanded in CMV-seropositive chronic hepatitis 
patients, have a significant decrease in the expression of 
CD161 and a significant increase in the expression of CD57 (69). 
In agreement with these data, our results show that the majority 
of NK cells do not coexpress CD57 and CD161, and that CMV 
seropositivity is associated not only with an increase in the expres-
sion of CD57 in CD56dim NK cells but also with a decrease in the 
expression of CD161 in this subset. The decreased expression of 
CD161 in NK cells from CMV-seropositive NK cells parallels 
the finding that CD161 is decreased on CD56+ NKT-like cells 
in CMV+ subjects compared with CMV-seronegative donors 
(70). Interestingly, it has also been shown that the expression 
of CD161 in CMV-specific cytotoxic T lymphocytes is very low 
(71). Considering the inhibitory capacity of CD161 on NK and 
T  lymphocytes cytokine production, these results support that 
the CMV-induced downregulation of CD161 receptor together 
with the expansion of polyfunctional response of CD57+  
NK cells and T- and NKT-like lymphocytes (14, 30, 69, 72, 73), 
contribute to the proinflammatory environment observed in 
CMV-seropositive healthy individuals.
Recent reports have strengthened the significance of T-bet 
and Eomes in NK cell biology (47). In mice, T-bet and Eomes 
are necessary for maintenance of peripheral NK cells, their 
deletion in mature NK cells results in reversion to an immature 
phenotype (46). These transcription factors also modulate many 
NK cell effector functions, including cytotoxicity and cytokine 
production (74, 75). In human NK cells, T-bet and Eomes are 
differentially expressed on NK cell subsets (45), supporting 
that they can regulate different functions in different NK cell 
subpopulations. Our results confirm and extend these results 
showing that the levels of T-bet and Eomes are modulated in 
peripheral blood NK cell subsets representing different matura-
tion stages, independently of aging and CMV serostatus. The 
expression of T-bet is lower in the CD56bright NK cells than in the 
CD56dim subset, whereas the expression of Eomes is higher in 
the CD56bright NK cells. The CD56dimCD57+ subset shows higher 
levels of T-bet and lower levels of Eomes than the CD56bright and 
CD56dimCD57− NK cells. These results agree with the finding that 
not only the expression of T-bet and Eomes but also the expres-
sion of CD57 marker, modulate in parallel with the increase of 
KIRs on NK cells, but they do not differ in licensed or unlicensed 
NK cells (76), supporting that NK cell maturation but not NK 
cell licensing is dependent on T-bet and Eomes modulation. The 
significance of T-bet and Eomes in the maturation of other NK 
cell subpopulations is also supported by the demonstration that 
other subsets of NK cells display distinct patterns of expression 
of these transcription factors. Thus, a subpopulation of tissue-
resident hepatic CD56bright NK-cells, adapted to the tolerogenic 
liver microenvironment, with reduced proinflammatory poten-
tial, and characterized by the expression of CXCR6, express high 
levels of Eomes and low levels of T-bet, a phenotype virtually 
absent from peripheral blood (77, 78).
Very little is known on the expression patterns of T-bet 
and Eomes within human NK cell subpopulations in clinical 
situations. In this work, we have analyzed the expression of these 
transcription factors in two circumstances, such as CMV chronic 
infection and aging, which have a profound impact in NK cell 
differentiation.
Our results show that CMV seropositivity in young indi-
viduals associates with a significant increase in the percentage of 
CD56dim NK cells expressing Eomes and a decreased percentage 
of T-bethi NK cells within the CD56dimCD57+ subset, suggesting 
that changes in the expression of these transcription factors are 
involved in CMV-induced remodeling of NK cells, characterized 
by the expansion of CD56dimCD57+ NK cells coexpressing NKG2C 
activating receptors (2, 14, 30, 60, 79). It has been reported that 
the level of expression of Eomes and T-bet is strongly reduced 
in NK cells from allogeneic hematopoietic stem cell transplanta-
tion recipients compared with healthy control subjects and that 
acute graft-versus-host disease and CMV reactivation are associ-
ated with further downregulation of T-bet (80) supporting the 
importance of these transcription factors in the generation and 
differentiation of NK cells and in the response against CMV after 
hematopoietic stem cell transplantation.
The analysis of the effect of age on Eomes expression 
showed a decreased expression in CD56bright NK cells from 
CMV-seronegative middle age donors compared with CMV-
seronegative young individuals, whereas in CMV-seropositive 
donors, its expression was significantly higher in the three NK cell 
subsets, in young donors compared with the middle age and old 
groups. The percentage of T-bethi NK cells was not significantly 
affected by age, independently of CMV serostatus. The effect of 
aging on the expression of transcription factors in NK cells is 
not known. It has been recently shown that impaired NK cell 
maturation in old mice is associated with a decreased expression 
of T-bet and Eomes in aged bone marrow NK cells. The use of 
bone marrow chimeras has revealed that the non-hematopoietic 
environment is responsible for the impaired maturation and 
function of NK cells, including the defective expression of T-bet 
and Eomes expression on NK cells (81). Considering that the 
defect in NK cell generation and in T-bet and Eomes expression 
in old mice is due to age alterations in non-hematopoietic envi-
ronment, a better understanding of these non-hematopoietic 
factors involved in NK cell differentiation is required for the 
definition of new strategies aiming to improve NK cell function 
in the elderly.
It has been shown that the expression of T-bet and Eomes 
is increased in non-naïve CD8+ T cells from aged subjects and 
that this increase correlated closely with the levels of CD57 
and KLRG1. In addition, it was shown that aging is associ-
ated with a decreased functionality of influenza virus-specific 
CD8+ T cells and increased expression of CD57, KLRG1, and 
T-bet (82), supporting that the increased expression of these 
transcription factors is related to the expansion of highly 
differentiated, senescent or exhausted, CD8+ T cells found in 
elderly individuals.
In conclusion, CMV latent infection has a profound impact 
on NK cells inducing significant changes in the expression of 
NK receptors, including the inhibitory receptors CD300a and 
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